Summary
ALPS Medical Breakthroughs ETF is an ETF - a fund traded on an exchange like a stock - run by ALPS Funds. Positions inside: 104. The ten largest make up 31% of the fund.
- Yearly costs
- 0.50%
- Fund size
- $172.7M
- Positions
- 104
- Running since
- 2014
What speaks for it
- Average yearly growth over the last ten years: 8.7%.
- It has been running since 2014.
What to watch
- 100% of the fund is in one sector (Healthcare).
- 89% of the fund is in one country (United States).
- Costs of 0.50% a year are above the middle of comparable funds (0.44%).
- In the last five years its price once dropped by 63% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -8.9%
- 3 months
- -15%
- This year
- +6.5%
- 1 year
- +30%
- 3 years
- +127%
- 5 years
- +18%
- 10 years
- +131%
- Avg. market cap
- $2.84B
- P/E
- -
- Forward P/E
- -
- P/S
- 7.6x
- P/B
- 3.6x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.00%
- ROIC
- 695.3%
- ROE
- -42.8%
- Gross margin
- -2,054.3%
- Operating margin
- -13,208.5%
- Net margin
- -11,755.2%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.95
Weighted average of the 50 largest companies, which make up 84% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Moderately concentrated- 1 CGCG Oncology, Inc. Common stock CGON 3.9%
- 2 OROruka Therapeutics, Inc. ORKA 3.5%
- 3 TVTravere Therapeutics, Inc. TVTX 3.4%
- 4 MAVeradermics, Incorporated MANE 3.3%
- 5 DFDefinium Therapeutics, Inc. DFTX 3.2%
- 6 EWEdgewise Therapeutics EWTX 3.0%
- 7 DNDianthus Therapeutics, Inc. DNTH 2.9%
- 8 RLRelay Therapeutics, Inc. RLAY 2.6%
- 9 AMAmylyx Pharmaceuticals, Inc. AMLX 2.4%
- 10 ACACADIA Pharmaceuticals ACAD 2.4%
Positions in the fund: 104. The ten largest make up 31% of it.
Composition as of Oct 18, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 89%
- Canada 2.4%
- United Kingdom 2.2%
- China 1.8%
- Other countries 4.4%
By company size
- Mid cap 56%
- Small cap 41%
- Micro cap 2.6%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (89%). Largest size group: Mid cap (56%).
What does it cost me?
Expensive- A year from $10,000
- $50.00
- Over 20 years
- $2,416
From every $10,000 invested the fund takes $50.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $2,416.
How has it done?
Growing over the long run- A year on average, 10 years
- +8.7%
- Deepest drop
- -63%
- Yearly volatility
- 32%
Average yearly growth over the last ten years: 8.7%. Deepest drop in these years: 63% below the earlier high.
Does it pay dividends?
Yes, it pays out- Last payment
- $1.17
The last payment was $1.17 on Dec 19, 2024.
Is it easy to buy and sell?
Yes- Traded a day
- $2.31M
- Shares a day
- 42K
On an average day about $2.31M of the fund changes hands.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 41 out of 100
Weight by Bulios Fair Price
- Undervalued 17%
- Fairly valued 1.4%
- Overvalued 82%
By Fair Price, 82% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 84% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
BB BBC Virtus Biotech Clinical Trials ETF | United States | 0.65% | $37.2M | +40% | Pays out | 38% |
FB FBTTX Fidelity Advisor Biotechnology Fund· mutual fund | - | - | $2.29B | +33% | Pays out | 23% |
FB FBTAX Fidelity Advisor Biotechnology Fund Class A· mutual fund | United States | - | $2.29B | +34% | Pays out | 23% |
FB FBTIX Fidelity Advisor Biotechnology Fund· mutual fund | - | - | $2.29B | +34% | Pays out | 23% |
TD TDNA T. Rowe Price Biotech ETF | United States | 0.55% | $9.09M | - | - | 22% |